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A randomized controlled trial has started in both Japan and Korea to evaluate the role of gas-
trectomy in the management of incurable advanced gastric cancer (AGC). Patients with AGC
diagnosed as having a single non-curable factor are randomized to gastrectomy plus che-
motherapy or chemotherapy alone. Surgeons at 33 specialized centers in Japan and at 15
high-volume hospitals in Korea will recruit 330 patients. Primary end-point is overall survival,
and secondary end-points are progression-free survival and adverse events associated with
either gastrectomy or chemotherapy.
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INTRODUCTION
The prognosis of advanced gastric cancer (AGC) patients
with non-curable factors, such as hepatic and peritoneal
metastases, is poor and most of them die within 1 year. For
these patients, the role of gastrectomy remains controversial.
However, gastrectomy is the preferred procedure for these
patients, even in the absence of any symptoms such as bleed-
ing and stenosis, based on the results of retrospective studies
showing that the procedure confers a survival beneﬁt. In the
literature (1–9), overall survival of 8.0–12.2 months is
reported with gastrectomy compared with 2.4–6.7 months
without gastrectomy, and the survival beneﬁt of gastrectomy
is obtained only in patients with a single non-curable factor.
Obviously, there should be enormous selection bias in these
data, generally speaking in favor of surgical patients.
Furthermore, chemotherapy alone has recently shown,
for the ﬁrst time, a median survival time over 1 year in
AGC deemed incurable (10). These situations warrant a pro-
spective randomized controlled trial designed to
investigate the role of gastrectomy in AGC with a single
non-curable factor. The Clinical Trial Review Committee of
the Japan Clinical Oncology Group (JCOG) approved the
following protocol on 18 December 2007, and the study was
activated on 4 February 2008.
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PROTOCOL DIGEST OF THE JCOG0705/
KGCA01
PURPOSE
The purpose of this trial was to investigate the superiority of
gastrectomy followed by chemotherapy to chemotherapy
alone in clinically stage IV AGC with a single non-curable
factor, in terms of survival beneﬁt and safety associated with
gastrectomy or chemotherapy.
STUDY SETTING
The study was a multi-institutional (33 specialized centers in
Japan and 15 high-volume hospitals in Korea) randomized
controlled trial.
RESOURCES
Grants-in-Aid for Cancer Research (17S-3, 17S-5), from the
Ministry of Health, Labor and Welfare, Japan. Grants for
Cancer Research, from the Korean Gastric Cancer Association,
Korea.
END-POINTS
The primary end-point is overall survival. The secondary
end-points are progression-free survival and adverse events
associated with gastrectomy or chemotherapy.
ELIGIBILITY CRITERIA
Tumors are staged according to the Japanese Classiﬁcation
of Gastric Carcinoma (11).
INCLUSION CRITERIA
Patients are included in the trial if they meet all of the fol-
lowing criteria: (i) histologically proven primary gastric ade-
nocarcinoma, (ii) presence of only one of the following
patterns of metastasis, which is conﬁrmed by both computed
tomography (CT) scan and staging laparoscopy (or open
laparotomy): (a) hepatic metastasis (H1) (2–4 lesions,
maximum diameter ,5 cm), (b) peritoneal dissemination
(P1) without massive ascites or intestinal obstruction or (c)
extensive para-aortic lymph node metastasis (No. 16a1 and/
or b2), (iii) clinical T1-3, (iv) no evidence of para-aortic
and/or retropancreatic lymph node metastasis (i.e. N0–2) in
the cases of hepatic or peritoneal metastasis, (v) no evidence
of other distant metastasis than H1, P1 or LN 16a1/b2, (vi)
no apparent pleural effusion, (vii) length of esophageal inva-
sion 3 cm or less with no need of thoracotomy for resection,
(viii) not stump carcinoma, (ix) aged 20–75 year old, (x)
performance status (PS) of 0 or 1 on Eastern Cooperative
Oncology Group (ECOG) scale, (xi) sufﬁcient oral intake
without active bleeding from the gastric tumor, (xii) no prior
treatment of chemotherapy or radiation therapy against any
other malignancies, and no prior treatment for gastric cancer
except EMR (endoscopic mucosal resection), (xiii) adequate
organ functions deﬁned as indicated below: (a) WBC
3000/mm3, WBC 12 000/mm3, (b) Hb 8.0 g/dl
without any transfusion 2 weeks before enrollment, (c) Plt
100 000/mm3, (d) AST 100 IU/l, (e) ALT 100 IU/l,
(f ) T.Bil 2.0 mg/dl, (g) Cr 1.2 mg/dl, (h) Ccr 60 ml/
min/body and (xiv) written informed consent.
EXCLUSION CRITERIA
Patients are excluded if they meet any of the following
criteria: (i) active double cancer (synchronous double cancer
and metachronous double cancer within ﬁve disease-free
years), excluding carcinoma in situ (lesions equal to intrae-
pithelial or intramucosal cancer), (ii) pregnant or breast-
feeding women, (iii) severe mental disorder, (iv) systemic
administration of corticosteroids, (v) medication of furu-
cytocin, fenytoin or warfarin, (vi) active bacterial infection
or mycosis, affecting systemic condition, (vii) unstable
angina or myocardial infarction within 6 months of the trial,
(viii) unstable hypertension, (ix) diabetes mellitus, uncon-
trolled or controlled with insulin, (x) severe respiratory
disease requiring continuous oxygen therapy.
RANDOMIZATION
After conﬁrmation of the above criteria, registration is made
by telephone call or fax to the JCOG Data Center in Japan,
and by web system to Seoul National University Hospital
(SNUH) Data Center in Korea. Patients are randomized in
each country by a minimization method of balancing the
arms according to institution, nodal status (N0–1/N2–3) and
non-curable factor (hepatic/peritoneal/para-aortic metastasis).
TREATMENT METHODS
GASTRECTOMY PLUS CHEMOTHERAPY
Either a total, distal or proximal gastrectomy with D1 lymph
node dissection is performed depending on the tumor
location with the metastatic lesions untouched. Neither
complete D2 lymphadenectomy nor combined resection of
adjacent organs except for gallbladder, mesocolon and
diaphragm is acceptable. Within 8 weeks after surgery, the
patient is placed on a chemotherapy regimen, S-1 þ CDDP.
Oral S-1 is administered at a dose of 80 mg/m2/day for 3
consecutive weeks followed by a 2-week rest. Cisplatin is
delivered on Day 8 at a dose of 60 mg/m2. This regimen is
repeated every 5 weeks until disease progression.
CHEMOTHERAPY ALONE
Patients receive the same chemotherapy as described above
without any operation until disease progression.
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FOLLOW-UP
Patients are assessed every months to detect any adverse
events with verbal interview, physical examination and
blood tests, including a complete blood cell count and
measurements of liver and renal function, until progressive
disease. Abdominal CT scan and measurements of CEA and
CA19-9 are carried out every 3 months.
STUDY DESIGN AND STATISTICAL METHODS
This trial is designed to evaluate the superiority of gas-
trectomy followed by chemotherapy to chemotherapy alone
in terms of overall survival. The hypothesis to be tested
is that 2-year overall survival on gastrectomy followed by
chemotherapy is greater than that (20–25%) obtained by
chemotherapy alone by 10%. If a 10% improvement in
a 2-year overall survival rate is demonstrated, gastrectomy
followed by chemotherapy will be the preferred treatment.
The planned sample size is 330, 165 cases per arm, with 2
years follow-up after 4 years of accrual. This will provide an
80% power with a one-sided alpha of 5%.
INTERIM ANALYSIS, MONITORING AND AUDIT
Two interim analyses are planned, with adjustments for
repeated comparisons taken into account by the Lan and
DeMets method. We use the O’Brien–Fleming-type alpha
spending function. The Data and Safety Monitoring
Committee (DSMC) of the JCOG independently reviews the
interim analysis report and will consider stopping the trial
early, in agreement with SNUH Data Center. Central moni-
toring is performed by the respective Data Center in each
country to ensure data submission, patient eligibility, proto-
col compliance, safety and on-schedule study progress. The
monitoring reports are submitted to and reviewed by the
respective Data Center independently every 6 months.
The monitoring summary is exchanged between the two
countries semiannually. Audits of the participating facilities
are also carried out independently in each country, and brief
summaries are exchanged.
PARTICIPATING INSTITUTIONS
Japan: Iwate Medical University, Sendai National Hospital,
Miyagi Cancer Center, Yamagata Prefectural Central
Hospital, National Defense Medical College, Saitama
Cancer Center, National Cancer Center Hospital East,
National Cancer Center Hospital, Tokyo Metropolitan
Komagome Hospital, Tokyo Medical and Dental University,
Cancer Institute Hospital, Tokyo Metropolitan Bokutoh
Hospital, Kanagawa Cancer Center, Niigata Cancer Center
Hospital, Nagaoka Chuo General Hospital, Tsubame
Rosai Hospital, Toyama Prefectural Central Hospital, Gifu
Municipal Hospital, Shizuoka Prefectural General Hospital,
Aichi Cancer Center, Fujita Health University, Kyoto 2nd
Red Cross Hospital, Kinki University, Osaka Medical Center
for Cancer and Cardiovascular Diseases, National Osaka
Medical Center, Osaka Medical College, Toyonaka
Municipal Hospital, Sakai Municipal Hospital, Itami City
Hospital, Wakayama Medical University, Hiroshima City
Hospital, National Shikoku Cancer Center, Oita University.
Korea: Ajou University Hospital, Chonnam University
Hwasun Hospital, Dong-A University Hospital, Hanyang
University Hospital, Kangnam St Mary’s Hospital, Korea
Cancer Center Hospital, Korea University Guro Hospital,
Kosin University Hospital, Kyungpook University Hospital,
National Cancer Center, Samsung Medical Center, Seoul
National University Hospital, Seoul National University
Bundang Hospital, Yonsei University Severance Hospital,
Yonsei University Youngdong Hospital.
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